Optimizing patient care and research: The Amsterdam dementia cohort

Journal of Alzheimer's Disease

Volumn 41, Issue 1, 2014, Pages 313-327

  Van Der Flier, Wiesje M ^a   Pijnenburg, Yolande A L ^a   Prins, Niels ^a   Lemstra, Afina W ^a   Bouwman, Femke H ^a   Teunissen, Charlotte E ^a   Van Berckel, Bart N M ^a   Stam, Cornelis J ^a   Barkhof, Frederik ^a   Visser, Pieter Jelle ^a   Van Egmond, Evan ^a   Scheltens, Philip ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; dementia; diagnosis; investigations; mild cognitive impairment; work up

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL PRACTICE; CLINICAL RESEARCH; DEMENTIA; DNA DETERMINATION; EARLY DIAGNOSIS; ELECTROENCEPHALOGRAPHY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK FACTOR; AGED; CLINICAL PATHWAY; COHORT ANALYSIS; FEMALE; INTERNET; MALE; MEDICAL RESEARCH; MIDDLE AGED; NETHERLANDS; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; AGED; ALZHEIMER DISEASE; BIOMEDICAL RESEARCH; COHORT STUDIES; CRITICAL PATHWAYS; DEMENTIA; EARLY DIAGNOSIS; FEMALE; HUMANS; INTERNET; MALE; MIDDLE AGED; NETHERLANDS; PATIENT CARE;

EID: 84902279951     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132306     Document Type: Article

References (72)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report ofthe NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
2. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Schel-tens P, Carillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
3. RománGC, Tatemichi TK, Erkinjuntti T, Cummings JL, Mas-deu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A (1993) Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250-260.
4. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE (2005). Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 65, 1863-1872.
5. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotempo-ral lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 51, 1546-1554.
6. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456-2477.
7. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Ogar JM, Rohrer JD, Black S, Boeve BF, Manes F, Dronkers NF, Vandenberghe R, Rascovsky K, Patterson K, Miller BL, Knopman DS, Hodges JR, Mesulam MM, Grossman M (2011) Classification of primary progressive aphasia and its variants. Neurology 76, 1006-1014.
8. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56, 303-308.
9. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279.
10. Cummings JL, Mega MS, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 44, 2308-2314.
11. Sheikh JA, Yesavage JA (1986) Geriatric depression scale (GDS): Recent findings and development of a shorter version. In: Clinical Gerontology: A Guide to Assessment and Intervention, Brink TL, ed, Howarth Press, New York.
12. Gelinas I, Gauthier L, McIntyre M, Gauthier S (1999) Development of a functional measure for persons with Alzheimer's disease: The disability assessment for dementia. Am J Occup Ther 53, 471-481.
13. Sikkes SA, de Lange-de Klerk ES, Pijnenburg YA, Gillissen F, Romkes R, Knol DL, Uitdehaag BM, Scheltens P (2012) A new informant-based questionnaire for instrumental activities of daily living in dementia. Alzheimers Dement 8, 536-543.
14. Sikkes SA, Knol DL, Pijnenburg YA, de Lange-de Klerk ES, Uitdehaag BM, Scheltens P (2013) Validation of the Amsterdam IADL Questionnaire (c), a new tool to measure instrumental activities of daily living in dementia. Neuroepi-demiology 41, 35-41.
15. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140, 566-572.
16. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
17. Derix M, Hofstede A, Teunisse S (1992) CAMDEX-N: De nederlandse versie van de Cambridge examination of mental disorders of the elderly. Zwets & Zeitlinger, Lisse.
18. Rey A (1964) L'examen clinique en psychologie, Presse de Universitaire de France, Paris.
19. Saan RJ, Deelman BG (1986) De 15-Woorden Test A en B. (Een voorlopige handleiding, in Dutch).
20. Lindeboom J, Schmand B, Tulner L, Walstra G, Jonker C (2002) Visual association test to detect early dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 73, 126-133.
21. Schmand B, Groenink SC, van den Dungen M (2008) [Letter fluency: Psychometric properties and Dutch normative data]. Tijdschr Gerontol Geriatr 39, 64-76.
22. Snijders J, Luteijn F, van der Ploeg F, Verhage F (1983) Handleiding Groninger intelligentie test. Swets & Zeitlinger, Lisse.
23. Warrington EK, James M (1991) The Visual Object and Space Perception Battery. Thames Valley Test Company, Bury St. Edmunds, UK.
24. Reitan RM (1958) Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 8, 271-276.
25. Lindeboom J, Matto D (1994) [Digit series and Knox cubes as concentration tests for elderly subjects]. Tijdschr Gerontol Geriatr 25, 63-68.
26. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J (1992) Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: Diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 55, 967-972.
27. Lehmann M, Koedam EL, Barnes J, Bartlett JW, Ryan NS, Pijnenburg YA, Barkhof F, Wattjes MP, Scheltens P, Fox NC (2012) Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. Neurobiol Aging 33, 627-633.
28. Koedam EL, Lehmann M, van der Flier WM, Scheltens P, Pijnenburg YA, Fox N, Barkhof F, Wattjes MP (2011) Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol 21, 2618-2625.
29. Pasquier F, Leys D, Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P (1996) Inter-and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol 36, 268-272.
30. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA (1987) MR signal abnormalities at 1. 5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 149, 351-356.
31. Cordonnier C, van der Flier WM, Sluimer JD, Leys D, Barkhof F, Scheltens P (2006) Prevalence and severity of microbleeds in a memory clinic setting. Neurology 66, 1356-1360.
32. Henneman WJ, Sluimer JD, Cordonnier C, Baak MM, Schel-tens P, Barkhof F, van der Flier WM (2009) MRI biomarkers of vascular damage and atrophy predicting mortality in a memory clinic population. Stroke 40, 492-498.
33. Liedorp M, van der Flier WM, Hoogervorst EL, Scheltens P, Stam CJ (2009) Associations between patterns of EEG abnormalities and diagnosis in a large memory clinic cohort. Dement Geriatr Cogn Disord 27, 18-23.
34. deWaal H, Stam CJ, Blankenstein MA, Pijnenburg YA, Schel-tens P, van der Flier WM (2011) EEG abnormalities in early and late onset Alzheimer's disease: Understanding heterogeneity. J Neurol Neurosurg Psychiatry 82, 67-71.
35. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Frederiksen JL Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Johnson MH, Krasulova E, Kuhle J, Magnone MC, Rajda C, Rejdak K, Schmidt HK, van Pesch V, Waubant E, Wolf C, Giovannoni G, Hemmer B, Tumani H, Deisenhammer F (2009) A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73, 1914-1922.
36. Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, Van Elk EJ, Scheltens P, Blankenstein MA (2010) Amyloid-beta (1-42), total tau, andphosphorylated tauascere-brospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 56, 248-253.
37. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtz-man DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC; Dominantly Inherited Alzheimer Network (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367, 795-804.
38. Krudop WA, Kerssens CJ, Dols A, Prins ND, Möller C, Schouws S, Barkhof F, van Berckel BN, Teunissen CE, van der Flier WM, Scheltens P, Stek ML, Pijnenburg YA (2013) Building a new paradigm for the early recognition of behavioral variant frontotemporal dementia: Late onset frontal lobe syndrome study. Am J Geriatr Psychiatry. doi: 10.1016/j.jagp.2013.02.002
39. van Assema DM, Lubberink M, Bauer M, van der Flier WM, Schuit RC, Windhorst AD, Comans EF, Hoetjes NJ, Tolboom N, Langer O, Muller M, Scheltens P, Lammertsma AA, van Berckel BN (2012) Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain 135, 181-189.
40. Binnewijzend MA, Schoonheim MM, Sanz-Arigita E, Wink AM, van der Flier WM, Tolboom N, Adriaanse SM, Damoi-seaux JS, Scheltens P, van Berckel BN, Barkhof F (2012) Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 33, 2018-2028.
41. Adriaanse SM, Sanz-Arigita EJ, Binnewijzend MA, Ossenkoppele R, Tolboom N, van Assema DM, Wink AM, Boellaard R, Yaqub M, Windhorst AD, van der Flier WM, Scheltens P, Lammertsma AA, Rombouts SA, Barkhof F, van Berckel BN (2014) Amyloid and its association with default network integrity in Alzheimer's disease. Hum Brain Mapp 35, 779-791.
42. Binnewijzend MA, Kuijer JP, Benedictus MR, van der Flier WM, Wink AM, Wattjes MP, van Berckel BN, Scheltens P, Barkhof F (2013) Cerebral blood flow measured with 3D pseudocontinuous arterial spin-labeling MR imaging in Alzheimer disease and mild cognitive impairment: A marker for disease severity. Radiology 267, 221-230.
43. Hooghiemstra AM, Eggermont LH, Scheltens P, van der Flier WM, Bakker J, de Greef MH, Koppe PA, Scherder EJ (2012) Study protocol: EXERcise and Cognition in Sedentary adults with Early-ONset dementia (EXERCISE-ON). BMC Neurol 12, 75-80.
44. Scheltens P, Twisk JW, Blesa R, Scarpini E, von Arnim CA, Bongers A, Harrison J, Swinkels SH, Stam CJ, de WH, Wurtman RJ, Wieggers RL, Vellas B, Kamphuis PJ (2012) Efficacy of Souvenaid in mild Alzheimer's disease: Results from a randomized, controlled trial. J Alzheimers Dis 31, 225-236.
45. Scheltens P, Kamphuis PJ, Verhey FR, Olde Rikkert MG, Wurtman RJ, Wilkinson D, Twisk JW, Kurz A (2010) Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial. Alzheimers Dement 6, 1-10.e1.
46. Most EI, Scheltens P, van Someren EJ (2010) Prevention of depression and sleep disturbances in elderly with memory-problems by activation of the biological clock with light-a randomized clinical trial. Trials 11, 19-23.
47. Scheltens P, Fox N, Barkhof F, De Carli C (2002) Structural magnetic resonance imaging in the practical assessment of dementia: Beyond exclusion. Lancet Neurol 1, 13-21.
48. Scheltens P, van de Pol L (2012) Impact commentaries. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: Diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 83, 1038-1040.
49. Boutet C, Chupin M, Colliot O, Sarazin M, Mutlu G, Drier A, Pellot A, Dormont D, Lehericy S (2012) Is radiological evaluationasgoodascomputer- basedvolumetrytoassess hip-pocampal atrophy in Alzheimer's disease? Neuroradiology 54, 1321-1330.
50. Schoonenboom NS, Pijnenburg YA, Mulder C, Rosso SM, Van Elk EJ, van Kamp GJ, van Swieten JC, Scheltens P (2004) Amyloid beta (1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 62, 1580-1584.
51. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA302, 385-393.
52. Blennow K, Hampel H, CSF markers for incipient Alzheimer's disease (2003) Lancet Neurol 2, 605-613.
53. Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, Galasko D, Hampel H, Hartmann T, Kapaki E, Lannfelt L, Mehta PD, Parnetti L, Petzold A, Pirttila T, Saleh L, Skinningsrud A, Swieten JC, Verbeek MM, Wiltfang J, Younkin S, Scheltens P, Blankenstein MA (2009) A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem 46, 235-240.
54. Teunissen CE, Verwey NA, Kester MI, van UK, Blanken-stein MA (2010) Standardization of assay procedures for analysis of the CSF biomarkers amyloid beta ((1-42)), tau, and phosphorylated tau in Alzheimer's disease: Report of an international workshop. Int J Alzheimers Dis 2010, 1-6.
55. del CM, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, Kapaki E, Kruse N (2012) Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: An update. Biomark Med 6, 419-30.
56. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, Cutler N, Dufour-Rainfray D, Fagan AM, Hee-gaard NH, Robin Hsiung GY, Hyman B, Iqbal K, Lachno DR, Lleó A, Lewczuk P, Molinuevo JL, Parchi P, Regen-iter A, Rissman R, Rosenmann H, Sancesario G, Schröder J, Shaw LM, Teunissen CE, Trojanowski JQ, Vanderstichele H, Vandijck M, Verbeek MM, Zetterberg H, Blennow K, Käser SA; Alzheimer's Association QC Program Work Group (2013) CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement 9, 251-261.
57. Vanderstichele HM, Shaw L, Vandijck M, Jeromin A, Zetter-berg H, Blennow K, Teunissen C, Engelborghs S (2013) Alzheimer disease biomarker testing in cerebrospinal fluid: A method to harmonize assay platforms in the absence of an absolute reference standard. Clin Chem 59, 710-712.
58. Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brienJ, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746.
59. Dubois B, Feldman HH, Jacova C, Cummings JL, DeKosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P (2010). Revising the definition of Alzheimer's disease: A new lexicon. Lancet Neurol 9, 1118-1127.
60. Tolboom N, Yaqub M, van der Flier WM, Boellaard R, Luurt-sema G, Windhorst AD, Barkhof F, Scheltens P, Lammertsma AA, van Berckel BN (2009) Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J Nucl Med 50, 191-197.
61. Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BN (2009) Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med 50, 1464-1470.
62. Tolboom N, van der Flier WM, Yaqub M, Koene T, Boel-laard R, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BN (2009) Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment. Neurology 73, 2079-2085.
63. Ossenkoppele R, Tolboom N, Foster-Dingley JC, Adriaanse SF, Boellaard R, Yaqub M, Windhorst AD, Barkhof F, Lam-mertsma AA, Scheltens P, van der Flier WM, van Berckel BN (2012) Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDGPET. Eur J Nucl Med Mol Imaging 39, 990-1000.
64. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, Hedrick S, Pappas V, Thies WH (2013) Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement 9, e-16.
65. Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Rowe C (2011) Longitudinal assessment of Abeta and cognitionin aging and Alzheimer disease. Ann Neurol 69, 181-192.
66. Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, Weiner MW, Jagust WJ (2012) Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 72, 578-586.
67. Altmann-Schneider I, Trompet S, de Craen AJ, van Es AC, Jukema JW, Stott DJ, Sattar N, Westendorp RG, van Buchem MA, van der Grond J (2011) Cerebral microbleeds are predictive of mortality in the elderly. Stroke 42, 638-644.
68. van der Vlies AE, Goos JD, Barkhof F, Scheltens P, van der Flier WM (2012) Microbleeds do not affect rate of cognitive decline in Alzheimer disease. Neurology 79, 763-769.
69. Goos JD, Henneman WJ, Sluimer JD, Vrenken H, Sluimer IC, Barkhof F, Blankenstein MA, Scheltens PH, van der Flier WM (2010) Incidenceofcerebral microbleeds:Alongitudinal study in a memory clinic population. Neurology 74, 1954-1960.
70. Cordonnier C, van der Flier WM (2011) Brain microbleeds and Alzheimer's disease: Innocent observation or key player? Brain 134, 335-344.
71. Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ (2011) Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 7, 367-385.
72. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M; Bapineuzumab 201 Clinical Trial Investigators (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061-2070.